Publications
Detailed Information
A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chun, Jung Won | - |
dc.contributor.author | Woo, Sang Myung | - |
dc.contributor.author | Lee, Sang Hyub | - |
dc.contributor.author | Choi, Jin Ho | - |
dc.contributor.author | Park, Namyoung | - |
dc.contributor.author | Kim, Joo Seong | - |
dc.contributor.author | Cho, In Rae | - |
dc.contributor.author | Paik, Woo Hyun | - |
dc.contributor.author | Lee, Woo Jin | - |
dc.contributor.author | Ryu, Ji Kon | - |
dc.contributor.author | Kim, Yong-Tae | - |
dc.date.accessioned | 2022-10-11T00:45:45Z | - |
dc.date.available | 2022-10-11T00:45:45Z | - |
dc.date.created | 2022-09-15 | - |
dc.date.issued | 2022-08 | - |
dc.identifier.citation | Therapeutic Advances in Medical Oncology, Vol.14 | - |
dc.identifier.issn | 1758-8340 | - |
dc.identifier.uri | https://hdl.handle.net/10371/185677 | - |
dc.description.abstract | Background: Nanoliposomal encapsulation of irinotecan (nal-IRI) with 5-fluorouracil and leucovorin (5-FU/LV) has shown a survival benefit for gemcitabine-pretreated patients with metastatic pancreatic adenocarcinoma (mPAC). The aim of this study was to evaluate the effectiveness and safety of nal-IRI with 5-FU/LV for use beyond second-line treatment after standard frontline therapy for mPAC. Method: This multicenter, retrospective, non-comparative observational study included mPAC patients who received nal-IRI plus 5-FU/LV as third- or later-line therapy after disease progression on first-line FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel. Results: In all, 128 patients who received nal-IRI plus 5-FU/LV beyond second-line treatment between October 2017 and July 2021 were analyzed. Most patients (82%) received nal-IRI plus 5-FU/LV as a third-line treatment. The median overall survival (OS) was 4.9 months and the median progression-free survival (PFS) was 2.4 months. Patients with better Eastern Cooperative Oncology Group (ECOG) performance status experienced significantly longer OS (ECOG 0, 8.7 months; ECOG 1, 4.8 months; ECOG 2, 2.9 months; p < 0.001) and PFS (3.9 months; 2.1 months; 1.5 months; p = 0.019). Patients who had not been previously treated with FFX or had a time to progression of 7 months or more on FFX experienced longer OS and PFS than those who did not (6.1 months and 5.6 versus 4.1 months, p = 0.053; 3.6 months and 2.4 versus 2.1 months, p = 0.002). The most common adverse events were neutropenia (56%) and anemia (51%). Conclusion: Our real-world data indicated that nal-IRI plus 5-FU/LV can be effective not only as second-line therapy, but also as third-line or later-line treatment in selected patients. Nal-IRI plus 5-FU/LV may be particularly beneficial for the survival of patients that maintain good general condition or those with favorable prior experience to irinotecan. | - |
dc.language | 영어 | - |
dc.publisher | SAGE Publications | - |
dc.title | A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma | - |
dc.type | Article | - |
dc.identifier.doi | 10.1177/17588359221119539 | - |
dc.citation.journaltitle | Therapeutic Advances in Medical Oncology | - |
dc.identifier.wosid | 000850203100001 | - |
dc.identifier.scopusid | 2-s2.0-85137231651 | - |
dc.citation.volume | 14 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Cho, In Rae | - |
dc.contributor.affiliatedAuthor | Ryu, Ji Kon | - |
dc.contributor.affiliatedAuthor | Kim, Yong-Tae | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.